$VAPR E-Cite' CEO and COO Invest Heavily, Converting Loans

New Post Public Reply Private Reply Replies (0) Message Board
louied91
127
$VAPR E-Cite' CEO and COO Invest Heavily, Converting Loans and Deferred Compensation to Restricted Stock at Double Market Price Reducing Related Party Payables by over 90% and Total Liabilities by over 50%

https://www.accesswire.com/942430/e-cite-ceo-...by-over-50

BOTHELL, WA / ACCESSWIRE / November 14, 2024 / VaporBrands International, Inc. dba E-Cite Motors Group, (OTC PINK:VAPR) announced that its CEO Barry Henthorn and COO Gene Langmesser have signed Board Resolutions converting loans and deferred compensation into restricted stock of (OTC PINK:VAPR) eliminating over 90% of related party payables.

Specifically, the related party payables resulted from consulting earnings and working capital contributions to the Company. The Compnay's CEO will convert $483,251 of related party payables to 48,325,149 restricted shares of the Company's common stock valued at $0.01 per share. The Company's COO will convert $193,300 related party payables to 19,330,000 restricted shares of the Company's common stock valued at $0.01 per share. The aggregate related party payables converted to common stock was $676,551 and 67,655,149 restricted shares of the Company's common stock.

This reduces the related party payables as of September 30, 2024 from $746,340 to $69,789 which is a reduction of more than 90%. In addition, total liabilities were reduced from $1,272,012 to $595,461 which is a reduction of more than 50%. Further details can be seen VAPRs Q3 Financial filings at www.otcmarkets.com under Subsequent Events section on the final page.

The shares will be issued with a restricted legend and will not become part of the public float until the company has completed a listing on a senior exchange and become fully reporting. Even if the company is successful in achieving these milestones, the shares will still be subject to insider restrictions and discloser requirements.

E-Cite Motors COO Gene Langmesser commented: "We are very confident in the new developments and progress of the company as we are gearing up to begin full production of our EV-GT sportscar. By removing the debt from the company while increasing my personal holdings at this time the company will be better positioned to attract non-dilutive capital."

"This is a major milestone in our initiatives to reduce the debt, tighten up the share structure, position the Company for growth, and increase shareholder value. We are very excited to begin production of or first vehicle the EV-GT " Added E-Cite Motors CEO Barry Henthorn.

E-Cite was the first company to get any vehicle approved by the National Highway Traffic Safety Administration (NHTSA) under the Low Volume Manufacturers Act of which E-Cite has four distinctly different vehicles approved. The EV-GT of which the new EV-C3 is anchored and two other E-Cite Vehicles, the EV-RT truck, and the EV-222 hyper car. E-Cite is free to manufacture them under a special exemption specifically (49 CFR 565.16(b)).

This allows E-Cite to produce its own VINs for the production of new vehicles. In addition, E-Cite has received a World Manufactures Identifier (WMI) under the Act registering it as a manufacturer for the sale of vehicles worldwide.

VaporBrands International Inc. (VAPR) Stock Research Links

VAPR Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 184

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 184

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 295

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 153

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 168

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 132

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading

Top 5 Most Recently Viewed Articles

Aalberts Shares Buyback Program Updates and Insights

Updated Category News Views 113

Overview of Aalberts' Share Buyback Program Aalberts has recently announced the progress of its ongoing share buyback program, giving investors and shareholders a detailed look into its current operations. This program is part of a strategic initiative to enhance shareholder value and demonstrate confidence in the company's long-term prospects. Recent Share Repurchase...

Continue Reading
American Water Named Among 2025 Most Responsible Companies

Updated Category News Views 206

American Water's Recognition on Newsweek’s List American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., is proud to announce its inclusion in Newsweek’s list of America’s Most Responsible Companies for 2025. This honor reflects American Water's unwavering commitment to environmental, social, and governance (ESG)...

Continue Reading
Pendulum Ink Reimagines Hip-Hop Education with New Model

Updated Category News Views 289

Pendulum Ink Innovates Online Hip-Hop Education Pendulum Ink, recognized as the world's first online hip-hop academy, has made headlines with its recent relaunch featuring a subscription-based model. This new structure is designed to provide flexible engagement tiers, making hip-hop education accessible to learners around the globe. The relaunch not only aims to educate...

Continue Reading
Revolutionizing Radiology: Mach7 Technologies Launches UnityVue

Updated Category News Views 90

Mach7 Technologies Introduces UnityVue for Radiology Mach7 Technologies is thrilled to announce the release of UnityVue, an advanced, AI-driven workflow orchestration solution designed to enhance patient care, alleviate radiologist burnout, and optimize diagnostic workflows. This innovative platform aims to create a more efficient radiology environment, making it a...

Continue Reading
Purina Partners with UC Davis to Enhance Pet Urinary Health

Updated Category News Views 150

Purina Teams Up with UC Davis School of Veterinary Medicine Nestlé Purina PetCare is thrilled to share a groundbreaking partnership with the University of California, Davis. This collaboration is focused on improving our understanding of urinary health in pets. With the support of a generous grant, this initiative represents a major step forward in scientific research...

Continue Reading